Penumbra, Inc. (NYSE:PEN) Shares Sold by Xponance Inc.

Xponance Inc. lowered its position in shares of Penumbra, Inc. (NYSE:PEN) by 3.9% in the fourth quarter, HoldingsChannel.com reports. The firm owned 8,152 shares of the company’s stock after selling 330 shares during the quarter. Xponance Inc.’s holdings in Penumbra were worth $2,051,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. RiverPark Advisors LLC acquired a new position in shares of Penumbra during the third quarter worth $42,000. Covestor Ltd boosted its stake in Penumbra by 357.9% in the third quarter. Covestor Ltd now owns 348 shares of the company’s stock valued at $84,000 after acquiring an additional 272 shares in the last quarter. Nisa Investment Advisors LLC boosted its stake in Penumbra by 496.7% in the fourth quarter. Nisa Investment Advisors LLC now owns 358 shares of the company’s stock valued at $90,000 after acquiring an additional 298 shares in the last quarter. Fifth Third Bancorp boosted its stake in Penumbra by 13.9% in the fourth quarter. Fifth Third Bancorp now owns 378 shares of the company’s stock valued at $95,000 after acquiring an additional 46 shares in the last quarter. Finally, JGP Global Gestao de Recursos Ltda. acquired a new position in Penumbra in the fourth quarter valued at $207,000. Institutional investors and hedge funds own 88.88% of the company’s stock.

Penumbra Price Performance

Shares of PEN opened at $203.02 on Tuesday. Penumbra, Inc. has a fifty-two week low of $180.93 and a fifty-two week high of $348.67. The company has a market capitalization of $7.86 billion, a price-to-earnings ratio of 87.89, a price-to-earnings-growth ratio of 2.00 and a beta of 0.51. The firm has a 50-day simple moving average of $233.18 and a 200-day simple moving average of $232.39. The company has a debt-to-equity ratio of 0.02, a quick ratio of 3.49 and a current ratio of 6.06.

Penumbra (NYSE:PEN) last announced its quarterly earnings data on Thursday, February 22nd. The company reported $0.76 EPS for the quarter, beating analysts’ consensus estimates of $0.71 by $0.05. The firm had revenue of $284.68 million during the quarter, compared to the consensus estimate of $286.62 million. Penumbra had a net margin of 8.59% and a return on equity of 7.49%. The firm’s revenue was up 28.7% compared to the same quarter last year. During the same quarter last year, the firm earned $0.16 earnings per share. On average, equities research analysts anticipate that Penumbra, Inc. will post 2.85 earnings per share for the current year.

Insider Activity at Penumbra

In related news, Director Don W. Kassing sold 170 shares of the firm’s stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $223.18, for a total value of $37,940.60. Following the completion of the sale, the director now owns 1,175 shares in the company, valued at $262,236.50. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, Director Arani Bose sold 7,500 shares of the firm’s stock in a transaction that occurred on Monday, March 4th. The shares were sold at an average price of $250.20, for a total transaction of $1,876,500.00. Following the completion of the transaction, the director now directly owns 164,294 shares of the company’s stock, valued at approximately $41,106,358.80. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Don W. Kassing sold 170 shares of the firm’s stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $223.18, for a total transaction of $37,940.60. Following the transaction, the director now directly owns 1,175 shares of the company’s stock, valued at $262,236.50. The disclosure for this sale can be found here. Insiders sold a total of 9,648 shares of company stock worth $2,369,903 over the last 90 days. Company insiders own 5.30% of the company’s stock.

Analyst Ratings Changes

Several research firms have issued reports on PEN. TheStreet upgraded shares of Penumbra from a “d+” rating to a “c-” rating in a research note on Friday, January 12th. JPMorgan Chase & Co. downgraded shares of Penumbra from an “overweight” rating to a “neutral” rating and decreased their price objective for the company from $284.00 to $250.00 in a research note on Friday, February 23rd. Canaccord Genuity Group restated a “buy” rating and issued a $284.00 price objective on shares of Penumbra in a research note on Friday, February 23rd. Piper Sandler restated an “overweight” rating and issued a $290.00 price objective on shares of Penumbra in a research note on Wednesday, April 3rd. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $289.00 target price on shares of Penumbra in a research note on Friday, February 23rd. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Penumbra has an average rating of “Moderate Buy” and an average target price of $304.45.

Penumbra Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.